Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Selinexor + Choline Salicylate in NHL, HL, Histiocytic/Dendritic Cell Neoplasms, or MM
NCT04640779Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor and choline salicylate in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), histiocytic and dendritic cell neoplasms and 1 more, sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose. Started Feb 2021; status: completed.
02
Drugs
selinexorcholine salicylate
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)histiocytic and dendritic cell neoplasmsmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04640779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640779.